ClinicalTrials.gg
CompletedNCT01925144Updated Jun 6, 2017Results posted

A Study of Baricitinib and Omeprazole in Healthy Participants

A Phase 1 interventional study of Baricitinib and Omeprazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to find out how the body will react to a study drug called baricitinib when taken with another drug called omeprazole.

For each participant, this study will include 2 periods in fixed order. The study will last approximately 25 days, not including screening.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical history and physical examination
  • Women not of due to surgical sterilization (at least 3 months after surgical hysterectomy, bilateral oophorectomy with or without hysterectomy, or bilateral tubal occlusion/ligation) confirmed by medical history, or menopause
  • Have a of 18 to 29 kilograms per square meter (kg/m\^2), inclusive, at screening

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to baricitinib, omeprazole, related compounds, or any components of the baricitinib or omeprazole formulations, or history of significant atopy
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological (including clotting disorders), or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have an (ANC) less than 2 × 10\^9 cells per liter (L) [2000 cells/microliter (μL)] at screening or Day -1. For abnormal values, a single repeat will be allowed
  • Intend to use over-the-counter or prescription medication (including drugs and substances known to alter gastric potential hydrogen (pH), such as proton pump inhibitors or over-the-counter antacid remedies and/or herbal supplements within 14 days prior to dosing and during the study (with the exception of hormone replacement therapy (HRT) and occasional paracetamol, which will be permitted at the discretion of the investigator), or intended use of vitamin supplements from Day 1 until discharge from the clinical research unit (CRU)
  • Have used or intend to use any drugs or substances that are known to be substrates, inhibitors, or inducers of cytochrome P450 3A4 () within 30 days prior to dosing and throughout the study
  • Are unable to tolerate or unwilling to undergo insertion of a nasogastric pH probe for assessment of gastric pH during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.

    Drug: Baricitinib

  • Experimental
    Baricitinib + Omeprazole

    Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).

    Drug: Baricitinib · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

    Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose

  2. PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib

    Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose

  3. PK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib

    Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose

07

Results

Posted Apr 21, 2017

Participant flow

Period 1 (Day 1 Through Predose Day 3)
Participant flow — Period 1 (Day 1 Through Predose Day 3)
MilestoneBaricitinib + Omeprazole
Started30
Received baricitinib30
Completed30
Not completed0
Period 2 (At Dosing Day 3 Through Day12)
Participant flow — Period 2 (At Dosing Day 3 Through Day12)
MilestoneBaricitinib + Omeprazole
Started30
Received baricitinib30
Received 8 doses of omeprazole30
Completed30
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
Time frame:
Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
nanograms/milliliter (ng/mL)BaricitinibBaricitinib + Omeprazole
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib99.2 ± 3276.8 ± 25
PrimaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Time frame:
Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
hoursBaricitinibBaricitinib + Omeprazole
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib1.00 (0.50 to 3.00)2.00 (0.75 to 6.00)
PrimaryPK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib
Time frame:
Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
PK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib
nanograms*hour/milliliter (ng*h/mL)BaricitinibBaricitinib + Omeprazole
PK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib663 ± 23712 ± 23

Adverse events

Collected over Baseline through study completion (up to Day 24).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib—0/30 (0%)5/30 (16.7%)
Omeprazole—0/30 (0%)8/30 (26.7%)
Baricitinib + Omeprazole—0/30 (0%)7/30 (23.3%)
Most frequent other events
Most frequent other events
EventBaricitinibOmeprazoleBaricitinib + Omeprazole
HeadacheNervous system disorders4/303/306/30
DiarrhoeaGastrointestinal disorders0/304/302/30
Abdominal pain upperGastrointestinal disorders0/303/300/30
FlatulenceGastrointestinal disorders1/302/300/30
NauseaGastrointestinal disorders2/301/300/30

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Baricitinib + Omeprazole
Mean44.1 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib + Omeprazole
Female8
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib + Omeprazole
Hispanic or Latino0
Not Hispanic or Latino30
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib + Omeprazole
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White29
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Baricitinib + Omeprazole
United Kingdom30
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 19, 2013
Start
Oct 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01925144
Responsible party
Sponsor
First posted
Aug 19, 2013
Start date
Oct 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion